Intravenous Immunoglobulin Market Forecast Reveals Where Future Industry Value Will Be Created
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Intravenous Immunoglobulin Market Forecast Highlighting Growth From $16.86 Billion To $23.43 Billion
The intravenous immunoglobulin market has experienced robust expansion in recent years. Projected to increase from $15.57 billion in 2025 to $16.86 billion in 2026, it is set to achieve a compound annual growth rate (CAGR) of 8.3%. Historically, this growth has been driven by a higher incidence of primary immunodeficiency diseases, progress in immunoglobulin purification methods, greater administration of intravenous immunoglobulin within hospital settings, enhanced awareness surrounding autoimmune disorders, and the scaling up of production capabilities for intravenous immunoglobulin.
The intravenous immunoglobulin market is projected to experience robust expansion in the coming years, with its value anticipated to reach $23.44 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.6%. This forecasted growth is fueled by several key factors, including a rising preference for home-based intravenous immunoglobulin (IVIG) therapy, the emergence of biosimilar IVIG products, the incorporation of automated infusion technologies, broader applications in treating neurological disorders, and increased opportunities in developing markets for immunoglobulin treatments. Notable developments shaping the landscape include trends such as tailored immunoglobulin therapies, the growing adoption of at-home IVIG administration, continued progress in biosimilar development and uptake, improvements in purification methods and safety measures, and the rollout of automated infusion systems.
Download A Free Sample Report For Comprehensive Market Insights:
Intravenous Immunoglobulin Market Demand Drivers: What Is Fueling Industry Growth?
The rising number of elderly individuals is anticipated to propel the intravenous immunoglobulin market. This demographic consists of people aged 65 and older. With advancing age, the immune system becomes less effective, resulting in a deficiency of antibodies. Consequently, immunoglobulins are necessary to supply these antibodies, boosting the demand for intravenous immunoglobulins and accelerating market expansion. For example, in January 2024, the Population Reference Bureau, a Kenya-based nonprofit, reported that the U.S. population aged 65 and over is projected to increase from 58 million in 2022 to 82 million by 2050—a 47% rise. The proportion of this age group within the total population is also expected to climb from 17% to 23% over the same timeframe. Therefore, the growing elderly population will continue to drive the advancement of the intravenous immunoglobulin market.
Intravenous Immunoglobulin Market Segment Breakdown: Which Categories Generate The Most Revenue?
The intravenous immunoglobulin market covered in this report is segmented –
1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications
4) By End-User: Hospitals, Clinics, Home Care
Intravenous Immunoglobulin Market Innovation Trends: Which Developments Are Transforming The Industry?
Key players in the intravenous immunoglobulin sector are concentrating on developing cutting-edge products, like medicines derived from plasma, and securing approvals from regulatory bodies such as the U.S. FDA to strengthen their market position. Receiving FDA clearance for an innovative IVIG treatment indicates that a new intravenous immunoglobulin therapy has been officially authorized by the United States Food and Drug Administration to address particular health conditions. For example, in June 2024, Biotest AG, a German company specializing in plasma protein and product supply, reported its first FDA authorization for Yimmugo, intended to manage primary immunodeficiencies. As an intravenous immunoglobulin, Yimmugo consists of pooled human plasma-extracted immunoglobulin G (IgG), which is vital for bolstering immune function in individuals suffering from PIDs. This clearance occurs amid a growing demand for therapies based on plasma, underscoring the necessity of effective interventions for those with weakened immune systems. Yimmugo expands Grifols’ current portfolio of intravenous and subcutaneous immunoglobulins, delivering additional choices for patients who depend on these critical medications.
Intravenous Immunoglobulin Market Key Players And Strategic Industry Positioning
Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.
Access The Complete Intravenous Immunoglobulin Market Report:
Intravenous Immunoglobulin Market Largest Region By Revenue And Market Share
North America was the largest region in the intravenous immunoglobulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
